Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES Influenza and Other Respiratory Viruses Pub Date : 2024-06-05 DOI:10.1111/irv.13311

Juliette Paireau, Cécile Durand, Sylvain Raimbault, Joséphine Cazaubon, Guillaume Mortamet, Delphine Viriot, Christophe Milesi, Elise Daudens-Vaysse, Dominique Ploin, Sabrina Tessier, Noémie Vanel, Jean-Loup Chappert, Karine Levieux, Ronan Ollivier, Jamel Daoudi, Bruno Coignard, Stéphane Leteurtre, Isabelle Parent-du-Châtelet, Sophie Vaux

{"title":"Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024","authors":"Juliette Paireau, Cécile Durand, Sylvain Raimbault, Joséphine Cazaubon, Guillaume Mortamet, Delphine Viriot, Christophe Milesi, Elise Daudens-Vaysse, Dominique Ploin, Sabrina Tessier, Noémie Vanel, Jean-Loup Chappert, Karine Levieux, Ronan Ollivier, Jamel Daoudi, Bruno Coignard, Stéphane Leteurtre, Isabelle Parent-du-Châtelet, Sophie Vaux","doi":"10.1111/irv.13311","DOIUrl":null,"url":null,"abstract":"<p>In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case–control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5–88.7) in the main analysis and 80.6% (61.6–90.3) and 80.4% (61.7–89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13311","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case–control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5–88.7) in the main analysis and 80.6% (61.6–90.3) and 80.4% (61.7–89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2023 年 9 月至 2024 年 1 月期间，Nirsevimab 对法国儿科重症监护病房住院呼吸道合胞病毒支气管炎病例的疗效。

2023 年 9 月，法国成为首批开始使用 nirsevimab（一种新型抗呼吸道合胞病毒（RSV）单克隆抗体）进行全国免疫接种的国家之一。我们利用来自儿科重症监护病房（PICU）网络的数据，旨在估算涅舍维单抗对法国 RSV 支气管炎重症病例的疗效。我们进行了一项基于阴性试验设计的病例对照研究，纳入了 20 个 PICU 报告的 288 名婴儿。在主要分析中，我们估计 nirsevimab 的有效率为 75.9% (48.5-88.7)；在两项敏感性分析中，我们估计 nirsevimab 的有效率分别为 80.6% (61.6-90.3) 和 80.4% (61.7-89.9)。这些真实世界的估计值证实了临床研究中观察到的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.